Diligence Reports. Within sixty (60) days after the end of each calendar year, COMPANY shall report in writing to HOSPITAL on progress made toward the objectives set forth in Section 3.1 during such preceding twelve (12) month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses entered into and marketing.
Appears in 6 contracts
Samples: Exclusive License Agreement, Exclusive License Agreement (Zeltiq Aesthetics Inc), Exclusive License Agreement (Zeltiq Aesthetics Inc)
Diligence Reports. Within sixty (60) days after the end of each calendar year, COMPANY Company shall report in writing to HOSPITAL Hospital on progress made toward the objectives set forth in Section 3.1 during such preceding twelve (12) 12 month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses entered into and marketing.
Appears in 6 contracts
Samples: Exclusive Patent License Agreement, Exclusive Patent License Agreement (Vicapsys Life Sciences, Inc.), Exclusive Patent License Agreement (Tiziana Life Sciences PLC)
Diligence Reports. Within sixty (60) days [***] after the end of each calendar year, COMPANY Company shall report in writing to HOSPITAL Hospital on progress made toward the objectives set forth in Section 3.1 during such preceding twelve (12) 12 month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses entered into and marketing.
Appears in 3 contracts
Samples: Exclusive Patent License Agreement (Alopexx, Inc.), Exclusive Patent License Agreement (Keros Therapeutics, Inc.), Exclusive Patent License Agreement (Keros Therapeutics, Inc.)
Diligence Reports. Within sixty (60) [* * *] days after the end of each calendar year, COMPANY Company shall report in writing to HOSPITAL Hospital on progress made toward the objectives set forth in Section 3.1 during such preceding twelve (12) 12 month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses entered into and marketing.
Appears in 3 contracts
Samples: Exclusive Patent License Agreement (Biohaven Pharmaceutical Holding Co Ltd.), Exclusive Patent License Agreement (Biohaven Pharmaceutical Holding Co Ltd.), Exclusive Patent License Agreement (Biohaven Pharmaceutical Holding Co Ltd.)
Diligence Reports. Within sixty (60) days after the end of each calendar year, COMPANY Company shall report in writing to HOSPITAL Hospital on progress made toward the objectives set forth in Section 3.1 during such preceding twelve (12) 12 month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses entered into and marketing. All diligence reports shall be considered the Confidential Information of Company.
Appears in 2 contracts
Samples: Exclusive Patent License Agreement (ArcherDX, Inc.), Exclusive Patent License Agreement (ArcherDX, Inc.)
Diligence Reports. Within sixty (60) [*] days after the end of each calendar year, COMPANY Company shall report in writing to HOSPITAL Hospital on progress made toward the objectives set forth in Section 3.1 during such preceding twelve (12) month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses entered into and marketing.
Appears in 2 contracts
Samples: Exclusive Patent License Agreement (Signal Genetics, Inc.), Exclusive Patent License Agreement (Signal Genetics, Inc.)
Diligence Reports. Within sixty (60) [***] days after the end of each calendar year, COMPANY Company shall report in writing to HOSPITAL Hospital on progress made toward the objectives set forth in Section 3.1 during such preceding twelve (12) -month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses entered into and marketing.
Appears in 2 contracts
Samples: Exclusive Patent License Agreement (Seer, Inc.), Exclusive Patent License Agreement (Seer, Inc.)
Diligence Reports. Within sixty Sixty (60) days after the end of each calendar year, COMPANY Company shall report in writing to HOSPITAL Hospital on progress made toward the objectives set forth in Section 3.1 during such preceding twelve Twelve (12) month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses entered into and marketing.
Appears in 2 contracts
Samples: License Agreement (Fluoropharma Medical, Inc.), License Agreement (Fluoropharma Medical, Inc.)
Diligence Reports. Within sixty (60) days after the end of each calendar year, COMPANY Company shall report in writing to HOSPITAL Hospital on progress made toward the objectives set forth in Section 3.1 during such preceding twelve (12) month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses entered into and marketing.
Appears in 2 contracts
Samples: Exclusive Patent License Agreement (ProQR Therapeutics B.V.), Exclusive Patent License Agreement (ProQR Therapeutics B.V.)
Diligence Reports. Within sixty (60) days after the end of each calendar year, COMPANY shall report in writing to HOSPITAL on progress made toward the objectives set forth in Section 3.1 during such preceding twelve (12) 12 month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses entered into and marketing.
Appears in 2 contracts
Samples: Exclusive License Agreement (T2 Biosystems, Inc.), Exclusive License Agreement (T2 Biosystems, Inc.)
Diligence Reports. Within sixty (60) [***] days after the end of each calendar year, COMPANY Company shall report in writing to HOSPITAL Hospital on progress made toward the objectives set forth in Section 3.1 during such preceding twelve (12) month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses entered into and marketing.
Appears in 1 contract
Samples: Exclusive Patent License Agreement (TScan Therapeutics, Inc.)
Diligence Reports. Within sixty (60) days after the end of each calendar year, COMPANY shall report in writing to HOSPITAL on progress made toward the objectives set forth in Section 3.1 during such preceding twelve (12) -month period, including, without limitation, progress on research and development, status of applications for regulatory approvals, manufacturing, sublicensing and the number of sublicenses entered into and marketing.
Appears in 1 contract
